TransCode Therapeutics, Inc.

NASDAQ (USD): TransCode Therapeutics, Inc. (RNAZ)

Last Price

1.20

Today's Change

+0.02 (1.69%)

Day's Change

1.14 - 1.28

Trading Volume

185,255

Overview

Market Cap

7 Million

Shares Outstanding

6 Million

Avg Volume

1,285,306

Avg Price (50 Days)

0.96

Avg Price (200 Days)

9.24

PE Ratio

0.00

EPS

-3885.98

Earnings Announcement

12-Aug-2024

Previous Close

1.18

Open

1.14

Day's Range

1.14 - 1.28

Year Range

0.42 - 128.0

Trading Volume

185,255

Price Change Highlight

1 Day Change

1.69%

5 Day Change

-11.76%

1 Month Change

48.77%

3 Month Change

73.66%

6 Month Change

-82.30%

Ytd Change

-81.42%

1 Year Change

-98.86%

3 Year Change

-99.97%

5 Year Change

-99.97%

10 Year Change

-99.97%

Max Change

-99.97%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment